ELVN Enliven Therapeutics, Inc.: institutional ownership and insider trading
223 funds reported holding $4.16B of Enliven Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $947M, with 63 new positions and 17 funds selling out; over the last 12 months insiders bought $0 and sold $76.9M on the open market.
Famous investors holding ELVN
- Ken Griffin (Citadel Advisors): $109M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $20.9M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $15.5M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.15M, 0.0% of the portfolio
Largest institutional holders of ELVN
- FMR LLC — $509M
- ORBIMED ADVISORS LLC — $344M
- Polar Capital Holdings Plc — $326M
- BlackRock, Inc. (BLK) — $221M
- Vestal Point Capital, LP — $203M
- Commodore Capital LP — $166M
- PRICE T ROWE ASSOCIATES INC /MD/ — $147M
- VANGUARD CAPITAL MANAGEMENT LLC — $130M
- CITADEL ADVISORS LLC — $109M
- Fairmount Funds Management LLC — $94.2M
Recent ELVN insider trades
- Oct 19, 2026: Collins Helen Louise sold 5,000 shares ($192K)
- Oct 19, 2026: Hohl Benjamin sold 6,018 shares ($232K)
- Oct 1, 2026: Garland J. Scott sold 13,000 shares ($607K)
- Sep 17, 2026: Collins Helen Louise sold 5,000 shares ($252K)
5%+ owners
- FMR LLC: 15.0% (Schedule 13G/A, filed Aug 6, 2026)
- ORBIMED ADVISORS LLC: 9.5% (Schedule 13D/A, filed Jun 24, 2026)
- Polar Capital Holdings Plc: 8.5% (Schedule 13G/A, filed Jun 22, 2026)
- Commodore Capital LP: 7.7% (Schedule 13G/A, filed May 15, 2026)
- Vestal Point Capital, LP: 5.4% (Schedule 13G/A, filed May 15, 2026)